To robustly test the efficacy and safety of DEspR inhibition in neutrophil-mediated secondary tissue injury, we used the LPS-encephalopathy rat model with high-mortality phenotype in order to be able to use survival as primary endpoint of efficacy (Figure 4A). This evidence concerns the gene FBXW7-AS1 and Encephalopathy.